HRV-based Training Effects in Athletes (HRV-btA)

May 25, 2020 updated by: María Carrasco Poyatos, Universidad de Almeria

Physiological and Psychological Effects of Heart Rate Variability Based Training in Endurance Athletes

Monitoring individual responses to training is an important key factor to prescribe to most effective training programs. Heart-rate variability (HRV) could be used for monitoring the training status of endurance athletes in order to detect the fatigue status and to assess the adaptation to training. This direct fatigue measuring method has been little used to prescribe or regulate exercise prescription. Moreover, it allows new possibilities for the training load prescription according to an athlete's status, the response to the training load, and the adaptation to training. Regardless HRV-guided training, the athlete performance could also be influenced by precompetitive mood and anxiety, which can also be reflected in the precompetitive HRV scores and the subjective effort perception.

Study Overview

Status

Completed

Detailed Description

Monitoring individual responses to training is an important key factor to prescribe to most effective training programs. A promising variable that is able to reflect positive or negative training adaptation is cardiac autonomic regulation. In general, a decreased training status is associated with a lower power output at the same submaximal heart rate and a slower heart rate recovery, whereas an increased training status is associated with an increased power output, the same submaximal heart rate, and a faster heart rate recovery.

In this line, heart-rate variability (HRV), which focuses on the variability of successive R-R intervals, have gained popularity in monitoring the training status of endurance athletes. This tool enables the detection of fatigue status and assesses the adaptation to training. After high intensity training or a short-term overreached period, there is a decrease in the resting HRV values, reflecting the effect of the fatigue. In addition, the increase of the performance after a training period is related to an increase in resting HRV. This direct fatigue measuring method has been little used to prescribe or regulate exercise prescription. Moreover, this HRV-guided training, also called day-to-day periodization, allows new possibilities for the training load prescription according to an athlete's status, the response to the training load, and the adaptation to training.

On the other hand, regardless HRV-guided training, the athlete performance could also be influenced by precompetitive mood and anxiety, which can also be reflected in the precompetitive HRV scores and the subjective effort perception. This is another interesting line that pretends to be clarified in this study.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Almería, Spain, 04120
        • University of Almeria

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Belonging to the Spanish Athletics Federation.
  • Training and running in Spanish Athletics Federation contest during at least two years.
  • Stay in the first third of the classification of the previous season last five races.

Exclusion Criteria:

  • Cardiovascular pathologies.
  • Parameters of blood pressure (BP) outside of normality.
  • Respiratory problems diagnosed.
  • Be in treatment of psychological problems.
  • Regular consumption of drug (s) with direct or indirect effects on the Nervous System (e.g., anxiolytics, antidepressants, neuroleptics).
  • Consumption of substances not permitted by the International Athletics Federation (IAF).
  • Punctual consumption of medication that could alter the performance due to suffering some disease related to cardiorespiratory system (e.g., influenza).
  • Do not attend at least the 90% of the workouts during the intervention.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HRV-Group
Athletes will train according to their basal HRV scores. If the resting HRV is higher tan their basal HRV, they will perform a high or moderate intensity training. If the resting HRV is lower, they will perform a low intensity training. If the resting HRV still lower, they will rest. They will not accumulate two or more days of high-moderate intensity training, nor two or more days of rest.
Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
Active Comparator: TRAD-Group
Athletes will train according to their trainer plan. Training will not be guided by their basal HRV scores.
Traditional endurance training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
VO2max
Time Frame: Change from baseline VO2max at 8 weeks
Maximal oxygen consumption in treadmill test
Change from baseline VO2max at 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
maximal heart rate
Time Frame: Change from baseline maximal heart rate at 8 weeks
maximal heart rate in the treadmill test
Change from baseline maximal heart rate at 8 weeks
maximal speed
Time Frame: Change from baseline maximal speed at 8 weeks
maximal speed in the treadmill test
Change from baseline maximal speed at 8 weeks
ventilatory thresolds
Time Frame: Change from baseline ventilatory thresolds at 8 weeks
ventilatory thresolds in the treadmill test
Change from baseline ventilatory thresolds at 8 weeks
respiratory quotient
Time Frame: Change from baseline respiratory quotient at 8 weeks
respiratory quotient in the treadmill test
Change from baseline respiratory quotient at 8 weeks
Time in running test
Time Frame: Change from baseline time at 8 weeks
Time in the 3000 meters running test
Change from baseline time at 8 weeks
Lactate change
Time Frame: Change from baseline Lactate at 8 weeks
Lactate change after the 3000m test
Change from baseline Lactate at 8 weeks
Speed in running test
Time Frame: Change from baseline speed at 8 weeks
Speed in the 3000 meters running test
Change from baseline speed at 8 weeks
Heart rate in running test
Time Frame: Change from baseline heart rate at 8 weeks
Heart rate in the 3000 meters running test
Change from baseline heart rate at 8 weeks
Börg scale after running test
Time Frame: Through study completion (8 weeks)
Subjective perceived exertion. Scores goes from 0 to 10. Higher scores indicate a higher perceived exertion.
Through study completion (8 weeks)
LnrMSSD score
Time Frame: Through study completion (8 weeks)
Parasympathetic tone and recovery indicator. There are no minimum or maximum values. They depend on the athlete recovery state. Higher scores indicate a better outcome.
Through study completion (8 weeks)
Mood score
Time Frame: Through study completion (8 weeks)
Precompetitive mood levels. Instrument: Profile of Mood States. Scores goes from 0 (low mood) to 4 (high mood).
Through study completion (8 weeks)
Anxiety score
Time Frame: Through study completion (8 weeks)
Precompetitive anxiety levels. Instrument: Revised Competitive State Anxiety Inventory-2. Scores goes from 1 (no anxiety) to 4 (a lot of anxiety).
Through study completion (8 weeks)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fat mass
Time Frame: Change from baseline body composition at 8 weeks
Percentage of fat mass
Change from baseline body composition at 8 weeks
Muscle mass
Time Frame: Change from baseline body composition at 8 weeks
Percentage of muscle mass
Change from baseline body composition at 8 weeks
Bone mass
Time Frame: Change from baseline body composition at 8 weeks
Percentage of bone mass
Change from baseline body composition at 8 weeks
Body water
Time Frame: Change from baseline body composition at 8 weeks
Percentage of body water
Change from baseline body composition at 8 weeks
Height
Time Frame: Change from baseline height at 8 weeks
Height in meters
Change from baseline height at 8 weeks
Weight
Time Frame: Change from baseline weight at 8 weeks
Weight in kilograms
Change from baseline weight at 8 weeks
Heart Rate Variability Change (LnrMSSD)
Time Frame: Change from Baseline Heart Rate Variability at 8 weeks
Parasympathetic tone and recovery indicator
Change from Baseline Heart Rate Variability at 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Alberto González Quílez, Master, Universidad de Almeria
  • Principal Investigator: Antonio Granero-Gallegos, PhD, Universidad de Almeria

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 7, 2019

Primary Completion (Actual)

December 7, 2019

Study Completion (Actual)

December 7, 2019

Study Registration Dates

First Submitted

October 24, 2019

First Submitted That Met QC Criteria

October 31, 2019

First Posted (Actual)

November 5, 2019

Study Record Updates

Last Update Posted (Actual)

May 27, 2020

Last Update Submitted That Met QC Criteria

May 25, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Emotions

Clinical Trials on HRV-based training

Subscribe